Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BY-NC-ND 4.0Biology Direct

Targeting ZP3 with chimeric antigen receptor macrophages: a novel immunotherapeutic strategy for hepatocellular carcinoma

  1. 1Department of Surgical Oncology, Lanzhou University Second Hospital, Lanzhou, China
  2. 2Key Laboratory of Environmental Oncology of Gansu Province, Lanzhou, China

Abstract

Background: Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality worldwide, underscoring the need for effective immunotherapeutic strategies. Here, we generated monoclonal antibodies against zona pellucida glycoprotein 3 (ZP3), developed ZP3-targeting chimeric antigen receptor macrophages (CAR-M), and evaluated their therapeutic potential in HCC.

Methods: The recombinant extracellular domain of human ZP3 was expressed in HEK293F cells and used to immunize mice. CD138⁺ plasma cells were enriched and subjected to antigen-specific single-cell screening. Paired immunoglobulin variable-region sequences were recovered by nested polymerase chain reaction, followed by antibody cloning, expression, and purification. An anti-ZP3 single-chain variable fragment was incorporated into a lentiviral CAR construct and expressed in THP-1 cells, which were subsequently differentiated into macrophage-like cells. The phagocytic activity, cytotoxicity, polarization phenotype, cytokine secretion, in vivo antitumor efficacy, biodistribution, and preliminary safety of ZP3-targeting CAR-M were evaluated in HCC cell-based assays and Huh7 xenograft models.

Results: Highly purified anti-ZP3 monoclonal antibodies were generated and shown to recognize membrane-associated ZP3 on Huh7 cells. Anti-ZP3 antibody treatment significantly suppressed tumor growth in peripheral blood mononuclear cell-reconstituted NOD-Scid mice. ZP3-targeting CAR-M exhibited efficient CAR expression and specific ZP3 binding, together with enhanced phagocytosis and cytotoxicity against HCC cells compared with control macrophages. Antigen engagement promoted an M1-like phenotype, characterized by increased CD80 and CD86 expression, reduced CD163 and CD206 expression, and enhanced secretion of IL-6, IL-1β, TNF-α, and IFN-γ. In Huh7 xenograft-bearing mice, systemic administration of CAR-M significantly delayed tumor progression. After treatment, body weight remained stable, most serum biochemical parameters responded basically normal, and major organs exhibited favorable tolerability.

Conclusions: ZP3 is a promising immunotherapeutic target in HCC. ZP3-directed antibodies and CAR-M demonstrated preclinical antitumor activity, supporting further development of ZP3-targeted immunotherapies.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13062-026-00941-x.

Related

  1. PM2.5 promotes migration of hepatocellular carcinoma by targeting miR-25
    Qiaoxin Li, Yuxuan Lu, Quanyu Guo +9
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Mechanistic insights into the anti-metastatic effects of calycosin from Ruanjianhugan tablets on hepatocellular carcinoma via CHEK1 targeting: a network analysis
    Peiqi Wan, Zhihong Liu, Kai Li +3
    The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of PharmacologyPeer-reviewedCC BY-NC 4.0Full textPharmacology & toxicologyPMC
  3. DCTN2 inhibited cellular senescence through targeting TRIM21 mediated MST2 ubiquitination and activation in hepatocellular carcinoma.
    Yanbo Wang, Yaomei He, Qin Yu +15
    TheranosticsPeer-reviewedCC BYFull textPhysiologyEurope PMC
  4. Targeting Ferroptosis-Mediated Tumor Microenvironment Remodeling in Hepatocellular Carcinoma: Therapeutic Resistance and Clinical Translation
    Hong Liu, Xiaoying Zhang, Jianfeng Bao +3
    Journal of Hepatocellular CarcinomaPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  5. Harnessing the Immune System in Hepatocellular Carcinoma Targeting: Mechanistic Insights and Therapeutic Potential of Natural Products and Traditional Chinese Medicine
    Hao L, Li L, Chen Y +5
    Drug Design, Development and TherapyPeer-reviewedCC BY-NCFull textOncologyDOAJEurope PMCPMC
BibTeX
@article{qu2026targeting,
  title = {{Targeting ZP3 with chimeric antigen receptor macrophages: a novel immunotherapeutic strategy for hepatocellular carcinoma}},
  author = {Caihao Qu and Wenzhang Wu and Yujie Wei and Xin Yan and Daijun Wang and Yumin Li},
  journal = {Biology Direct},
  year = {2026},
  month = aug,
  doi = {10.1186/s13062-026-00941-x},
  url = {https://doi.org/10.1186/s13062-026-00941-x},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Targeting ZP3 with chimeric antigen receptor macrophages: a novel immunotherapeutic strategy for hepatocellular carcinoma
AU  - Caihao Qu
AU  - Wenzhang Wu
AU  - Yujie Wei
AU  - Xin Yan
AU  - Daijun Wang
AU  - Yumin Li
PY  - 2026
DA  - 2026/08/17
JO  - Biology Direct
DO  - 10.1186/s13062-026-00941-x
UR  - https://doi.org/10.1186/s13062-026-00941-x
AB  - Background: Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality worldwide, underscoring the need for effective immunotherapeutic strategies. Here, we generated monoclonal antibodies against zona pellucida glycoprotein 3 (ZP3), developed ZP3-targeting chimeric antigen receptor macrophages (CAR-M), and evaluated their therapeutic potential in HCC.  Methods: The recombinant extracellular domain of human ZP3 was expressed in HEK293F cells and used to immunize mice. CD138⁺ plasma cells were enriched and subjected to antigen-specific single-cell screening. Paired immunoglobulin variable-region sequences were recovered by nested polymerase chain reaction, followed by antibody cloning, expression, and purification. An anti-ZP3 single-chain variable fragment was incorporated into a lentiviral CAR construct and expressed in THP-1 cells, which were subsequently differentiated into macrophage-like cells. The phagocytic activity, cytotoxicity, polarization phenotype, cytokine secretion, in vivo antitumor efficacy, biodistribution, and preliminary safety of ZP3-targeting CAR-M were evaluated in HCC cell-based assays and Huh7 xenograft models.  Results: Highly purified anti-ZP3 monoclonal antibodies were generated and shown to recognize membrane-associated ZP3 on Huh7 cells. Anti-ZP3 antibody treatment significantly suppressed tumor growth in peripheral blood mononuclear cell-reconstituted NOD-Scid mice. ZP3-targeting CAR-M exhibited efficient CAR expression and specific ZP3 binding, together with enhanced phagocytosis and cytotoxicity against HCC cells compared with control macrophages. Antigen engagement promoted an M1-like phenotype, characterized by increased CD80 and CD86 expression, reduced CD163 and CD206 expression, and enhanced secretion of IL-6, IL-1β, TNF-α, and IFN-γ. In Huh7 xenograft-bearing mice, systemic administration of CAR-M significantly delayed tumor progression. After treatment, body weight remained stable, most serum biochemical parameters responded basically normal, and major organs exhibited favorable tolerability.  Conclusions: ZP3 is a promising immunotherapeutic target in HCC. ZP3-directed antibodies and CAR-M demonstrated preclinical antitumor activity, supporting further development of ZP3-targeted immunotherapies.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13062-026-00941-x.
SN  - 1745-6150
ER  -